This 5-year long IP-cure-B project, which started on January 1st 2020, aims at developing novel curative concepts against chronic hepatitis B virus.
To do so, the project organization will combine:
- A proof of concept clinical trial of a combination of 2 novel compounds combination stimulating innate immunity;
- A preclinical HBV immune therapy platform in humanized mice combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses;
- Extensive virologic and immune profiling to identify correlates of cure in patients;
- The integration of large biological and clinical datasets to identify predictive response factors;
- A cost-effectiveness modelling of new therapeutic interventions to facilitate the implementation by national health systems.
The IP-cure-B project is funded by the European Horizon 2020 programme with a total budget of 10 million euros. The consortium, whose lead partner is the Cancer Research Center of Lyon (CRCL), gathers 14 partners, including: 10 universities in France, Switzerland, Italy, Greece, Germany and Spain; 2 industrial pharmaceutical companies (USA), one patients association (Belgium) and one company specialized in technology transfer in France.